Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02327546 · ClinicalTrials.gov registry record · Phase 1

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

A Phase 1 study of Healthy Volunteers, sponsored by Akebia Therapeutics.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT02327546 is a Phase 1 study of Healthy Volunteers that has completed, run by Akebia Therapeutics. The registered enrollment target is 10 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02327546, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Akebia Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.

Conditions Studied

Interventions

  • DRUG Ferrous Sulfate
  • DRUG AKB-6548

Study Locations (1)

Michigan

  • - Kalamazoo

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2014-12
Est. Completion 2015-02
Phase Phase 1

Sponsor

Akebia Therapeutics

24 total trials

What the Registry Record Tells You About NCT02327546

The ClinicalTrials.gov registry entry for NCT02327546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Ferrous Sulfate is the first listed.

NCT02327546 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02327546 about?

NCT02327546 is a clinical study titled "Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548". The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.

What is the current status of trial NCT02327546?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12. Estimated completion is 2015-02.

What conditions does trial NCT02327546 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02327546?

The interventions under investigation include: Ferrous Sulfate (DRUG), AKB-6548 (DRUG).

Who is sponsoring clinical trial NCT02327546?

This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02327546 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.